Immuno-Oncology | Specialty

James Allison Discusses the Potentiation of Checkpoint Blockage with Oncolytic Viruses

August 5th 2014

James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, Giant of Cancer Care, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.

Herbst Tackles Key Questions in Emerging PD-1/PD-L1 Immunotherapy for NSCLC

August 2nd 2014

Emerging agents and pressing research questions in immunotherapy were reviewed in depth during the 15th Annual International Lung Cancer Congress, with Roy S. Herbst, MD, PhD, of the Yale Cancer Center, leading the way.

Dr. Papadimitrakopoulou Discusses the Lung-MAP Trial

August 2nd 2014

Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the Lung-MAP trial, which uses next-generation sequencing as a screening test rather than screening for one mutation.

Dr. Ramalingam Discusses the Utility of Tecemotide in NSCLC

August 1st 2014

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the utility of the vaccine tecemotide as treatment for non-small cell lung cancer.

Immunotherapy Advances in Melanoma

July 28th 2014

Melanoma care has fortunately undergone a whirlwind of changes over the past several years. Novel immunotherapies are perhaps the most exciting recent development in cancer care because patients can enjoy long-term benefit from these treatments, meaning that they are possibly "cured."

Frontline Nivolumab Leads to Early, Durable Responses in NSCLC

July 25th 2014

One-third (30%) of chemotherapy-naïve non–small cell lung cancer (NSCLC) patients treated with nivolumab, an anti-PD-1 immune checkpoint antibody, responded to treatment in a phase I study.

Immunotherapy Combination Receives Breakthrough Designation for Pancreatic Cancer

July 21st 2014

The combination of the immunotherapy CRS-207 and the vaccine GVAX Pancreas has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic pancreatic cancer.

Future Immunotherapy Strategies in Cancer

July 18th 2014

Checkpoint Inhibitors Under Exploration in RCC

July 18th 2014

Return of Interferon in RCC

July 18th 2014

Potential Immunotherapy Combinations in RCC

July 18th 2014

PD-1 Combinations Explored in RCC

July 18th 2014

Immunotherapy Combination Strategies in RCC

July 18th 2014

Sequencing Checkpoint Inhibitors in NSCLC

July 18th 2014

Optimizing Checkpoint Inhibition in NSCLC

July 18th 2014

Immune Checkpoint Inhibitors in NSCLC

July 18th 2014

Evolving Renal Cell Carcinoma Treatment Paradigm

July 18th 2014

Rini Explores PD-1 Inhibition in Renal Cell Carcinoma

July 18th 2014

Development of Checkpoint Inhibitors for GU Cancers

July 18th 2014

Checkpoint Inhibition in Renal Cell Carcinoma

July 18th 2014